Seven years of experience with zygomycosis in Iran: a seasonal disease

Dear Editor,

Zygomycosis, earlier considered as rare entity, is being reported with increasing frequency in recent years.1 Classically described predisposing factors include poorly controlled diabetes, especially when associated with ketoacidosis, corticosteroid use, immunosuppression therapy for solid organ transplant or bone marrow transplant, neutropenia or neutrophil dysfunction associated with leukemia/lymphoma.2,3 In one study in Lebanon, it has been reported that mucormycosis incidence appears to be seasonal in the Eastern Mediterranean and clustering of onset of invasive mucormycosis begins around May and ends in October.4 In order to understand the whole gamut of the disease in the Iranian scenario, we undertook a retrospective analysis of such cases diagnosed with histopathologic confirmation in our institute over the last seven years (2003-2009). In this study we reported 27 patients with zygomycosis from 61 cases with suspected mucormycosis from a single center (Hzt Rasool-e-Akram Hospital, a tertiary care center), with special reference to its prevalence, sites of involvement, underlying diseases, time of diagnosis and treatment strategy.

Higher prevalence rate (29.6%) was observed in 2009. Rhino-orbito-cerebral type (100%) was the only presentation which can be categorized as nasal-paranasal sinuses (77.8%), orbital (11.1%) and nasal-paranasal sinuses-orbital (11.1%) involvement. Diabetes mellitus (in 55.7% of cases) was the most common underlying condition followed by hematologic malignancy (22.2%). Twenty-six cases treated with combination of aggressive surgical debridement of necrotic tissue and amphotericin-B except for one case treated with amphotericin-B alone. Medical therapy included conventional amphotericin B (CAB) in most cases and in one patient liposomal amphotericin B was used. In this study, onset of symptoms occurred in the summer and autumn in 21 out of 27 patients, showing a significant seasonal pattern in Iran (p = 0.001), as had been reported in Lebanon. In Beirut, weather pattern analysis revealed clustering of onset of invasive mucormycosis at the end of a dry, warm period, which begins around May and ends in October,4 which was similar to the time of occurring symptoms in our patients (Figure 1).

The study highlights the importance of increased awareness for early diagnosis of zygomycosis and aggressive management. Mucormycosis incidence appears to be seasonal in Iran. This disease and its treatments are still associated with severe morbidity, disfigurement and disability.

REFERENCES